ReShape Lifesciences Inc (NASDAQ:RSLS)’s traded shares stood at 76814.0 during the last session, with the company’s beta value hitting 1.16. At the close of trading, the stock’s price was $2.37, to imply a decrease of -2.07% or -$0.05 in intraday trading. The RSLS share’s 52-week high remains $414.99, putting it -17410.13% down since that peak but still an impressive 5.91% since price per share fell to its 52-week low of $2.23. The company has a valuation of $5.65M, with an average of 0.42 million shares in intraday trading volume over the past 10 days and average of 2.90 million shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for ReShape Lifesciences Inc (RSLS), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give RSLS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy.

ReShape Lifesciences Inc (NASDAQ:RSLS) trade information

After registering a -2.07% downside in the last session, ReShape Lifesciences Inc (RSLS) has traded red over the past five days. The 5-day price performance for the stock is -0.42%, and -64.89% over 30 days. With these gigs, the year-to-date price performance is -99.18%. Short interest in ReShape Lifesciences Inc (NASDAQ:RSLS) saw shorts transact 0.95 million shares and set a 0.15 days time to cover.

RSLS Dividends

ReShape Lifesciences Inc has its next earnings report out on 2025-Apr-04. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

ReShape Lifesciences Inc (NASDAQ:RSLS)’s Major holders

ReShape Lifesciences Inc insiders hold 10.63% of total outstanding shares, with institutional holders owning 0.73% of the shares at 0.81% float percentage. In total, 0.73% institutions holds shares in the company.